国家药品集中带量采购中选价与协议期满接续价格的衔接研究OA

Objective This study aims to analyze the progress of China's national volume-based drug procurement(NVBP),renewal,summarize the policy linkage between NVBP and renewal upon agreement expiry,and to provide suggestions for improving renewal policies.Methods Selection results and renewal procurement plans from NVBP Rounds 1-6 were compiled.Descriptive statistics were employed to examine NVBP winning prices,renewal winning prices,and the number of successful bidders.Results As of December 2024,agreements for 234 medicines had expired,of which 232 had completed the renewal process.Core renewal procurement consortia,led by Henan,Shanghai,Guangdong,and Jiangsu,emerged.Overall,renewal prices for the first 6 rounds of medicines continued to decline,with an average reduction of approximately 15%.However,17.7%of medicines saw price rebounds during the renewal.The magnitude of price changes varied across consortia due to different methodologies.Price dispersion for the same product after renewal fluctuated:differentials widened in Round 1 but narrowed in Round 3(P＜0.05).Regionally,during the NVBP phase,winning prices in western China shifted from 1.0%higher than the national average initially to 0.4%below post-renewal.Conclusions Renewal procurement generally led to further price reductions following NVBP,although prices for some products rebounded.Different renewal mechanisms influenced price outcomes,and price disparities across products and regions remain notable.Future efforts should focus on evaluating the effects of different renewal methods,promoting transparency in renewal work,strengthening price fluctuation monitoring,improving inter-regional price coordination,and aligning renewal policies with the governance of medicines with the same generic name,dosage form,strength,and made by the same manufacturer.